Pre-made Maftivimab benchmark antibody ( Whole mAb, anti-Zaire Ebolavirus GP therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Maftivimab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Maftivimab is a Zaire ebolavirus glycoprotein-directed human monoclonal antibody that is part of the fixed-dose combination atoltivimab/maftivimab/odesivimab that is used for the treatment of Zaire ebolavirus (Ebola virus).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-332-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Maftivimab biosimilar, Whole Mab: Anti-Zaire Ebolavirus GP therapeutic antibody
INN Name	Maftivimab
Target	Zaire Ebolavirus GP
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Preregistration
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Regeneron Pharmaceuticals
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Ebola virus infections
Development Tech	na